<PAPER>
  <mode2 name="11700329_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Nonsteroidal Anti-inflammatory Drugs Suppress T-cell Activation by Inhibiting p38 MAPK Induction*<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">In addition to antagonizing inflammation by inhibiting the activity of cyclooxygenases (COX), nonsteroidal anti-inflammatory drugs (NSAID) block T-cell activation.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
      <s sid="3">The immunosuppressant activity of NSAID correlates with their ability to block transcription factors required for the expression of inducible response genes triggered by T-cell antigen receptor (TCR) engagement.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="4">Whereas the inhibition of nuclear factor-&#954;B by aspirin and sodium salicylate can be partly accounted for by their binding to I&#954;B kinase-&#946;, the broad range of transcriptional targets of NSAID suggests that the products of COX activity might affect one or more among the early steps in the TCR-signaling cascade.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
      <s sid="5">Here we show that the inhibition of NF-AT activation by NSAID correlates with a selective inhibition of p38 MAP kinase induction.<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="6">The suppression of TCR-dependent p38 activation by NSAID can be fully overcome by prostaglandin E<sub>2</sub>, underlining the requirement for COX activity in p38 activation.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="7">Furthermore, the inhibition of COX-1 results in defective induction of theCOX-2 gene, which behaves as an early TCR responsive gene.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="8">The data identify COX-1 and COX-2 as integral and sequential components of TCR signaling to p38 and contribute to elucidate the molecular basis of immunosuppression by NSAID.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
      <s sid="9">Nonsteroidal anti-inflammatory drugs (NSAID)<sup>1</sup> block the activity of cyclooxygenases (COX), which catalyze the first step in the biosynthesis of prostaglandins (PG) and related eicosanoids.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
      <s sid="10">Two COX isoforms have been identified in eucaryotic cells.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
      <s sid="11">Although closely related by their enzymatic activity, COX-1 and COX-2 are implicated in different facets of the interaction of cells with their internal and external environments.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
      <s sid="12">COX-1 is constitutively expressed in most cells and is thought to play an important role in tissue homeostasis.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
      <s sid="13">In contrast, COX-2 is inducibly expressed in a more limited array of cell types in response to proinflammatory and mitogenic stimuli and is considered as the crucial mediator of inflammation (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">1</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
      <s sid="14">In agreement with the dominant role of COX-2 in inflammation, COX-2-selective NSAID have anti-inflammatory activity but limited unwanted side effects such as gastric damage and hemorrhage, typical of nonselective NSAID, which are likely to be accounted for by the inhibition of COX-1 (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">2</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
      <s sid="15">NSAID harbor additional immunomodulatory properties that have been correlated with their ability to block the activation of transcription factors implicated in the expression of proinflammatory cytokines and are likely to result, at least in part, from their well characterized activity on COX as exemplified by the inhibition of NF-&#954;B by cyclopentenone PG through covalent modification of I&#954;B kinase &#946; (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-1">3</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
      <s sid="16">However, additional COX-independent targets of NSAID are emerging, including I&#954;B kinase itself (<xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-1">4</xref>) and the nuclear receptor peroxisome proliferator-activated receptor &#948; (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">5</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
    </p>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
      <s sid="17">Although the principal cellular targets of NSAID are inflammatory cells such as macrophages and neutrophils, NSAID suppress T-cell proliferation, expression of surface activation markers such as CD25 and CD71, and the production of cytokines such as interleukin-2, interferon-&#947;, and tumor necrosis factor-&#945; (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">6-9</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
      <s sid="18">The immunosuppressant activity of NSAID correlates with their ability to block transcription factors required for the expression of inducible response genes triggered by the T-cell antigen receptor (TCR) following encounter with antigens, including NF-&#954;B, NF-AT, and activated protein 1 (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-2">5</xref>, <xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-2">6</xref>, <xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">9</xref>, <xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">10</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
      <s sid="19">The broad range of transcriptional targets of NSAID suggests that these drugs not only inhibit the distal components of individual transcription factor activation pathways but might also affect one or more steps in the early TCR-signaling cascade leading to transcription factor activation, potentially implicating COX in this process.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
      <s sid="20">In support for a potential role of COX in T-cell activation, COX-1 is constitutively expressed in T-cells, whereas the gene encoding COX-2 is inducibly activated as an early response gene in response to T-cell-activating stimuli (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-2">9</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
    </p>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
      <s sid="21">Here we have assessed the effect of NSAID on the TCR-signaling cascade.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/></s>
      <s sid="22">Using as a read-out NF-AT activation, we show that NSAID affect the MAP kinase cascade and specifically the activation of p38 MAP kinase, an effect that can be reversed by PGE<sub>2</sub> and is therefore dependent on COX activity.<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
      <s sid="23">Furthermore, the inhibition of COX-1 results in defective induction of COX-2 expression in response to TCR engagement, highlighting a sequential role of COX-1 and COX-2 in TCR signaling to p38.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
    </p>
    <SEC>
      <TITLE>EXPERIMENTAL PROCEDURES</TITLE>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cells and Reagents</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="24">Cell lines included a stably transfected Jurkat T-cell line expressing luciferase under the control of a trimer of the distal NF-AT binding site on the human interleukin-2 gene promoter (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">11</xref>), the monocyte line U937, and the Raji B-leukemia cell line.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
        <s sid="25">A stably transfected Jurkat T-cell line expressing luciferase under the control of a trimer of a NF-&#954;B binding site was generated as described previously (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-2">11</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
        <s sid="26">Peripheral blood mononuclear cells were isolated from whole blood by density centrifugation on Ficoll-Paque (Amersham Biosciences, Inc.) and subsequently depleted of macrophages by adherence.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="27">NSAID, SB203580, PD098059, and PGE<sub>2</sub> were purchased from <xref class="inline-ad-match" href="/cgi/redirect-inline?ad=Calbiochem" rel="external-nw">Calbiochem</xref> and Sigma.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="28">Phosphospecific antibodies recognizing the phosphorylated active forms of p38 and Erk1/Erk2 were from <xref class="inline-ad-match" href="/cgi/redirect-inline?ad=Cell%20Signaling%20Technology" rel="external-nw">Cell Signaling Technology</xref> (Beverly, MA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="29">Anti-p38 and anti-Erk2 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA), anti-actin mAb was from Amersham Pharmacia, and anti-COX-2 mAb was from Transduction Laboratories (Lexington, UK).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="30">IgG antibodies from OKT3 hybridoma supernatants were purified on Mabtrap (Amersham Biosciences, Inc.) and titrated by flow cytometry.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="31">Anti-IgM antibodies were purchased from Cappel (Durham, NC).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
        <s sid="32">All NSAID at the highest concentration used were tested for lack of toxicity by trypan blue exclusion.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="33">RAV-2 reverse transcriptase and Taqpolymerase were purchased from Takara Shutzo Co. (Shiga, Japan) and Roche Diagnostics SpA (Milan, Italy).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Activations, Immunoblots, and Luciferase Assays</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="34">To assay p38 and Erk1/Erk2 phosphorylation, 2&#8211;5 &#215; 10<sup>6</sup> Jurkat cells or PBL were activated by TCR cross-linking for 1 min at 37&#8201;&#176;C using the anti-CD3 mAb OKT3 as described previously (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">12</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/></s>
        <s sid="35">Macrophages and U937 cells were activated with 10 &#956;g/ml LPS (Sigma) for 10 min at 37&#8201;&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="36">Raji cells were activated by surface Ig cross-linking for 1 min at 37&#8201;&#176;C using anti-IgM antibodies.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
        <s sid="37">To analyze COX-2 expression, cells were activated either by TCR/CD3 cross-linking on secondary antibody-coated plates using OKT3 mAb (PBL) or 10 &#956;g/ml LPS (macrophages and U937) or by a combination of phorbol 12-myristate 13-acetate (50 ng/ml) and A32187 (100 ng/ml) for 16&#8211;24 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="38">NSAID or carrier were added to the culture medium 1 h prior to activation, and PGE<sub>2</sub> was added to culture medium 30 min prior to activation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="39">Cell lysates, obtained as described previously (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-2">12</xref>), were separated by SDS-PAGE, transferred to nitrocellulose filters, and subjected to immunoblot using peroxidase-labeled secondary antibodies (Amersham Biosciences) and a chemoluminescence detection kit (Pierce).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="40">To assay NF-AT activation, reporter Jurkat cells were activated either by CD3 cross-linking on a secondary antibody-coated plate using OKT3 mAb or by a combination of phorbol 12-myristate 13-acetate (100 ng/ml) and <xref href="/external-ref?link_type=GEN&amp;access_num=A23187">A23187</xref> (500 ng/ml) as described previously (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-3">11</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/></s>
        <s sid="41">NSAID or carrier was added 10 min prior to activation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
        <s sid="42">With the exception of time course experiments, cells were collected 5 h after activation and processed for luciferase assays as described previously (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-2">10</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
        <s sid="43">All samples were in duplicate, and each experiment was repeated 3&#8211;5 times.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Reactive Oxygen Species (ROS) Measurements</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="44">5 &#215; 10<sup>5</sup> cells/sample were resuspended in RPMI 1640 medium supplemented with 10 &#956;g/ml insulin, 5.5 &#956;g/ml transferrin, 6.5 ng/ml sodium selenite (Life Technologies, Inc.), and 20 &#956;<span class="sc">m</span> 2&#8242;,7&#8242;dichlorofluorescein diacetate medium (Sigma) and preincubated 30 min in the dark at room temperature.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="45">Carrier or NSAID were added, and cells were further incubated for 10 min on ice.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
        <s sid="46">Cells were subsequently spun, resuspended in the same medium, added with saturating concentrations of OKT3, and incubated for 30 min on ice.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="47">After two washes in phosphate-buffered saline/1% serum, cells were resuspended in 500 &#956;l of 2&#8242;,7&#8242;dichlorofluorescein diacetate medium, added with carrier or NSAID, incubated for further 30 min at 37&#8201;&#176;C, washed in phosphate-buffered saline/1% serum, and analyzed by flow cytometry in a Becton Dickinson FACScan (San Jose, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Reverse Transcription-PCR</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="48">Total RNA was extracted from Jurkat cells and either not activated or activated for 2, 4, 6, 8, and 16 h by TCR/CD3 cross-linking as described above using the RNA WIZ reagent (Ambion Inc, Austin, Texas).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="49">Reverse transcription-PCR was carried out using as first strand oligo(dT), whereas pairs of primers specific for human COX-2 (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-3">9</xref>) andGAPDH were used for cDNA amplification.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
        <s sid="50">cDNAs were amplified as described previously (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-4">9</xref>) in a Perkin-Elmer 2400 Thermal Cycler (Norwalk, CT).<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="51">PCR products were separated by agarose gel electrophoresis, and the intensity of the ethidium bromide-stained bands was quantitated by laser densitometry.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="52">The identity of theCOX-2-specific reverse transcription-PCR product was confirmed by automatic sequencing.<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Transfections and Confocal Microscopy</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="53">Confocal microscopy was carried out on Jurkat cells transiently transfected by the DEAE/dextran procedure as described previously (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-3">12</xref>) with the plasmid pEGFP/NF-AT1-D (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-1">13</xref>), either as such or following treatment for 20 min with 500 ng/ml <xref href="/external-ref?link_type=GEN&amp;access_num=A23187">A23187</xref> in the presence or absence of either 500 ng/ml cyclosporin A (Sandoz, East Hanover, NJ) or 600 &#956;<span class="sc">m</span> ibuprofen, using a Leica Microsystems confocal microscope (Heidelberg, Germany).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Sequence Analysis</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="54">Scanning of the human COX-2gene promoter (GenBank<sup>TM</sup> accession number <xref href="/external-ref?link_type=GEN&amp;access_num=AF276953">AF276953</xref>) for transcription factor binding sites was carried out using the matrix search program TRANSFAC MatInspector (<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">14</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>RESULTS AND DISCUSSION</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="55">To assess their impact on the TCR-signaling cascade, we assayed the capacity of NSAID to inhibit the activation of the transcription factor NF-AT using as a read-out a reporter Jurkat T-cell line stably transfected with a plasmid encoding firefly luciferase under the control of NF-AT (<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-4">11</xref>).<CoreSc1 atype="GSC" type="Goa" conceptID="Goa3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="56">The nonselective COX inhibitors, aspirin and ibuprofen, the COX-1-selective inhibitor resveratrol (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">15</xref>), and the COX-2-selective inhibitor NS-398 (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">16</xref>) all inhibited in a dose-dependent fashion the activation of NF-AT induced either by triggering the TCR/CD3 complex with agonistic mAb (Fig. <xref class="xref-fig" href="#F1" rid="xref-fig-1-1">1</xref>) or pharmacologically using a combination of phorbol ester and a calcium ionophore (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
        <s sid="57">A similar profile of inhibition was also observed in a Jurkat line stably transfected with an NF-&#954;B/luciferase reporter and activated using the same pharmacological agonists (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
        <s sid="58">Hence, both COX-1 and COX-2 activities are required for TCR signaling in T-cells.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
        <s sid="59">Although COX-2-specific mRNA was detectable as early as 2 h after stimulation (Fig. <xref class="xref-fig" href="#F2" rid="xref-fig-2-1">2</xref> A), NS-398 only partially blocked NF-AT (Fig. <xref class="xref-fig" href="#F1" rid="xref-fig-1-2">1</xref>) and NF-&#954;B (data not shown) activation, suggesting a dominant role for the costitutively expressed COX-1 in this process.<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="60">TCR triggering initiates a tyrosine kinase-based signaling cascade leading within minutes to the activation of two main pathways, the Ras/MAPK and the Ca<sup>2+</sup>/calcineurin pathways, which synergistically activate NF-AT (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">17</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        <s sid="61">We assessed the effect of NSAID on both pathways.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
        <s sid="62">The inhibitors of both Erk and p38 MAPKs reduced NF-AT activation in response to TCR engagement (Fig. <xref class="xref-fig" href="#F1" rid="xref-fig-1-3">1</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
        <s sid="63">However TCR-induced p38 activity but not Erk1/Erk2 activity was dramatically inhibited both by the nonselective and by the COX-1-selective NSAID as assessed by immunoblot analysis of Jurkat T-cell lysates with phosphospecific antibodies (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-1">3</xref> A).<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
        <s sid="64">Consistent with the lack of COX-2 expression before cell stimulation (Fig. <xref class="xref-fig" href="#F2" rid="xref-fig-2-2">2</xref> A and Ref. <xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-5">9</xref>), no effect on early p38 activation was observed in the presence of the COX-2 inhibitor NS-398.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
        <s sid="65">Similar results were obtained on purified peripheral blood lymphocytes (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="66">Hence, whereas Erk and p38 MAPKs are both required for TCR signaling to NF-AT, NSAID selectively inhibited p38 activation.<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="67">The inhibition of p38 by both the nonselective and the COX-1-selective NSAID was also observed in Raji B-cells stimulated with anti-IgM antibodies (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="68">Although both mitogenic stimuli and oxidative stress can induce p38 activation (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">18</xref>), no effect of NSAID on p38 activation was observed either in normal LPS-activated macrophages or in H<sub>2</sub>O<sub>2</sub>-treated Jurkat T-cells (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-2">3</xref> B).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="69">Hence, NSAID selectively affect coupling of the mitogenic pathways triggered by the T-cell and B-cell antigen receptors to p38 activation.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
        <s sid="70">Whereas an increase in ROS, which contributes to p38 (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">19</xref>) activation, is induced by TCR engagement (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">20</xref>), no effect of any of the NSAID was observed on the TCR-dependent up-regulation of intracellular ROS with the exception of resveratrol, which has anti-oxidant properties (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-2">15</xref>) (data not shown).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="71">The data are in agreement with a role for ROS upstream of COX (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-2">1</xref>) and rule out the molecules implicated in the inducible ROS production as the target of NSAID responsible for their inhibitory effect on p38 activation.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-17">
        <s sid="72">NSAID did not affect the Ca<sup>2+</sup>/calcineurin pathway.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="73">As shown in Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-3">3</xref> D, NF-AT localization was completely cytosolic in Jurkat cells transiently transfected with a construct encoding green fluorescent protein-tagged NF-AT1 in the absence of stimulation, whereas a massive NF-AT translocation to the nucleus fully repressible by cyclosporin A was observed following treatment with a calcium ionophore.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
        <s sid="74">Ibuprofen did not affect the inducible nuclear translocation of NF-AT (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-4">3</xref> D).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
        <s sid="75">Hence, the suppression of NF-AT activation by NSAID is achieved by inhibition of the MAPK pathway and specifically of p38 activation but not of the Ca<sup>2+</sup>/calcineurin pathway.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="76">Of note, although in heterologous cells, active p38 has been shown to dampen NF-AT activity by promoting its phosphorylation-dependent export from the nucleus (<xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-1">21</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
        <s sid="77">In Jurkat T-cells, both NSAID and the p38 inhibitor SB203580 blocked NF-AT activation (Fig. <xref class="xref-fig" href="#F1" rid="xref-fig-1-4">1</xref>) in agreement with the requirement for p38 in interleukin-2 production (<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-1">22</xref>), suggesting that p38 might play opposing roles in the early activation and subsequent deactivation of gene expression.<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-18">
        <s sid="78">The block by NSAID of TCR-dependent p38 activation suggests that the products of COX activity are required for TCR signaling.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
        <s sid="79">PGE<sub>2</sub> indeed increased both the low basal level of NF-AT activity and its response to TCR triggering (Fig. <xref class="xref-fig" href="#F1" rid="xref-fig-1-5">1</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
        <s sid="80">Furthermore, the treatment of Jurkat cells with PGE<sub>2</sub> resulted in the up-regulation of p38 activity, but not Erk1/Erk2, in the absence of stimulation (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-5">3</xref> C).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
        <s sid="81">Of note, PGE<sub>2</sub> could fully overcome the inhibition of TCR-dependent p38 activation by both ibuprofen (data not shown) and the COX-1-selective inhibitor resveratrol (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-6">3</xref> C).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs8" novelty="None" advantage="None"/></s>
        <s sid="82">Hence, the reduction in PGE<sub>2</sub> synthesis by COX can account for the inhibitory effect of NSAID on TCR-dependent p38 and NF-AT activation.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/></s>
        <s sid="83">In agreement with a role for COX upstream of p38 activation, PGE<sub>2</sub> failed to overcome the inhibition of NF-AT activation by the p38 inhibitor SB203580 (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs9" novelty="None" advantage="None"/></s>
        <s sid="84">p38 can be activated by distinct pathways triggered by mitogenic stimuli and cellular stress (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-2">18</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
        <s sid="85">The selective effect of NSAID on the activation of p38 triggered by the TCR and B-cell antigen receptor as opposed to LPS or H<sub>2</sub>O<sub>2</sub> (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-7">3</xref>, A and B) suggests that PGE<sub>2</sub>, which is produced in response to all these stimuli, does not directly activate p38 but a component upstream of p38 in the antigen receptor-signaling cascade.<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
        <s sid="86">Specifically, because tyrosine kinase-dependent pathways leading to Erk and p38 activation are believed to diverge at the level of the small GTPases Ras and Rac, respectively (<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">23</xref>), our data indicate a requirement for COX in the serine-threonine kinase cascade initiated by Rac.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-19">
        <s sid="87">p38 activity is required both for COX-2 gene expression and for post-transcriptional stabilization of COX-2 mRNA (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-1">24</xref>, <xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-1">25</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="88">The block in p38 activation by nonselective and COX-1-selective NSAID (Fig.<xref class="xref-fig" href="#F3" rid="xref-fig-3-8">3</xref> A) suggests that COX-1, which is constitutively expressed in T-cells (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-6">9</xref>), is implicated in the initial activation of p38 and might therefore be required for the induction of COX-2 expression.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp3" novelty="None" advantage="None"/></s>
        <s sid="89">To assess this possibility, we analyzed COX-2 expression in normal PBL.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa4" novelty="None" advantage="None"/></s>
        <s sid="90">TCR/CD3 stimulation as well as a combination of phorbol ester and calcium ionophore induced the expression of COX-2, albeit at levels significantly lower than in macrophages stimulated with LPS or pharmacological agonists (Fig. <xref class="xref-fig" href="#F2" rid="xref-fig-2-3">2</xref> B).<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
        <s sid="91">Of note, the monocyte line U937 constitutively expressed high levels of COX-2 (Fig.<xref class="xref-fig" href="#F2" rid="xref-fig-2-4">2</xref> B), which were parallelled by a high constitutive p38 activity (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-9">3</xref> B) in support of a key role for p38 in COX-2 expression.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
        <s sid="92">A pretreatment of PBL with the COX-1 inhibitor resveratrol completely blocked the TCR-dependent expression of COX-2 (Fig. <xref class="xref-fig" href="#F2" rid="xref-fig-2-5">2</xref> C).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs10" novelty="None" advantage="None"/></s>
        <s sid="93">Hence, COX-1 participates in the TCR-dependent induction of the gene encoding COX-2 probably by contributing to p38 activation.<CoreSc1 atype="GSC" type="Con" conceptID="Con11" novelty="None" advantage="None"/></s>
        <s sid="94">In agreement with the lack of effect of NSAID on LPS-dependent p38 activation in macrophages (Fig. <xref class="xref-fig" href="#F3" rid="xref-fig-3-10">3</xref> B), the induction of COX-2 expression by LPS is not impaired in COX-1<sup>&#8722;/&#8722;</sup> macrophages (<xref class="xref-bibr" href="#ref-26" rid="xref-ref-26-1">26</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs11" novelty="None" advantage="None"/></s>
        <s sid="95">Interestingly, p38 is required for NF-AT activation (Fig. <xref class="xref-fig" href="#F1" rid="xref-fig-1-6">1</xref>) and interleukin-2 expression (<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-2">22</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
        <s sid="96">Furthermore, cyclosporin A, which potently blocks NF-AT activation, also inhibits the induction of COX-2 gene expression, suggesting a role for NF-AT in this process.<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="97">In support of this possibility, scanning of the &#8764;500-bp region upstream of theCOX-2 gene containing the essential elements for its transcriptional regulation (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-1">27</xref>) revealed four potential NF-AT binding sites at positions &#8722;308/&#8722;297, &#8722;292/&#8722;281, &#8722;109/&#8722;98 and &#8722;80/&#8722;69.<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-20">
        <s sid="98">The immunosuppressant activity of NSAID on T-cells underlines a role for COX activity not only in the induction of proinflammatory cytokine gene expression during inflammation but also in the normal process of lymphocyte activation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="99">COX-2 has indeed been identified as an early response gene in peripheral T-cells (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-7">9</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="100">Furthermore, genetic and pharmacological evidence supports a key role for COX-1, specifically mediated by PGE<sub>2</sub> in the CD4<sup>&#8722;</sup>CD8<sup>&#8722;</sup>to the CD4<sup>+</sup>CD8<sup>+</sup> transition during thymocyte development (<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-1">28</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="101">COX-2-mediated PGE<sub>2</sub> synthesis by thymic stromal cells is also required for the maturation of CD4<sup>+</sup>thymocytes (<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-2">28</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
        <s sid="102">Our data show that COX-1 is a strategic component of the TCR-signaling cascade in that it promotes the activation of p38 and of transcription factors regulated by this MAPK.<CoreSc1 atype="GSC" type="Con" conceptID="Con12" novelty="None" advantage="None"/></s>
        <s sid="103">Among the transcriptional targets of these factors is COX-2.<CoreSc1 atype="GSC" type="Con" conceptID="Con13" novelty="None" advantage="None"/></s>
        <s sid="104">In this scenario, the initial burst of ROS production following TCR engagement, as well as the rapid early increase in the concentration of arachidonic acid due to the sequential activity of phospholipase C&#947; and cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>), would result in the up-regulation of COX-1 activity and increased synthesis of PG, thereby promoting p38 activation.<CoreSc1 atype="GSC" type="Con" conceptID="Con14" novelty="None" advantage="None"/></s>
        <s sid="105">This would in turn lead to COX-2 expression and a delayed phase of PG synthesis.<CoreSc1 atype="GSC" type="Con" conceptID="Con15" novelty="None" advantage="None"/></s>
        <s sid="106">In this context, the partial inhibition of NF-AT activation by the COX-2 inhibitor NS-398 (Fig. <xref class="xref-fig" href="#F1" rid="xref-fig-1-7">1</xref> and Ref. <xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-8">9</xref>) suggests that COX-2-dependent PG production might contribute to sustaining NF-AT activity at later stages of T-cell activation.<CoreSc1 atype="GSC" type="Con" conceptID="Con16" novelty="None" advantage="None"/></s>
        <s sid="107">Interestingly, mast cells from cPLA<sub>2</sub><sup>&#8722;/&#8722;</sup> mice fail to express COX-2 in response to cytokines, however arachidonic acid restores COX-2 expression (<xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">29</xref>), supporting our proposed role for COX-1-dependent PG production in the regulation ofCOX-2 transcription.<CoreSc1 atype="GSC" type="Con" conceptID="Con17" novelty="None" advantage="None"/></s>
        <s sid="108">Collectively, our data not only provide novel insight into the mechanisms underlying the immunosuppressant activity of NSAID in T-cells but suggest that selective p38 inhibitors might be a valid alternative to classical immunosuppressants as a tool to control T-cell activation in disease.<CoreSc1 atype="GSC" type="Con" conceptID="Con18" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>ACKNOWLEDGEMENTS</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21">
        <s sid="109">We thank Sonia Grassini for technical assistance, Giancarlo Benocci for secretarial assistance, Luisa Lanfrancone for useful suggestions, and John L. Telford, Antonio Lanzavecchia, and Gioacchino Natoli for productive discussions and critical reading of the manuscript.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Footnotes</TITLE>
    </SEC>
    <SEC>
      <TITLE>REFERENCES</TITLE>
    </SEC>
  </BODY>
</PAPER>